• Reuters, Kyodo

  • SHARE

Prime Minister Fumio Kishida said Monday that the government would consider granting conditional early approval for the oral COVID-19 treatment being developed by Shionogi & Co., with his remarks coming as the firm prepares to start a late-stage global trial.

Shionogi chief executive Isao Teshirogi told reporters that the company could file for early approval of the drug in Japan as soon as next week, and that it could deliver enough doses for 1 million people by the end of March.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW

PHOTO GALLERY (CLICK TO ENLARGE)